Robert J. Soiffer, MD, Dana-Farber Cancer Institute
Advertisement
Articles by Robert J. Soiffer, MD, Dana-Farber Cancer Institute
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC
3
September Roundup of FDA Approvals in Oncology: 8 Decisions to Know
4
Two Dana-Farber Researchers Receive Prestigious New Innovator Award from the National Institutes of Health
5